Skip to main content

Advertisement

Table 3 Characteristics of 4 randomized trials comparing gemcitabine to gemcitabine plus other cytotoxic agents

From: Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer

Reference Year n Treatment regimen Stage IV (%) Male (%) PS 0–1 (%)
Oettle 2005 282 Gem 1000 mg/m2 for 3 of 4 wks 92 54 88
   283 Gem 1250 mg/m2 d1, 8 + Pemetrexed 500 mg/m2 d8 q 3 wks 90 60 85
Rocha Lima 2004 180 Gem 1000 mg/m2 for 7 of 8 wks, then wkly for 3 of 4 wks 81 53 74
   180 Gem 1000 mg/m2 + Irinotecan 100 mg/m2 d1+8 q 3 wks 82 57 78
Stathopoulos 2006 70 Gem 900 mg/m2 for 3 of 4 wks 86 60 86
   60 Gem 900 mg/m2 d1, 8 + Irinotecan 300 mg/m2 d8, q 4 wks 78 65 87
O'Reilly 2004 174 Gem 1000 mg/m2 for 7 of 8 wks, then wkly for 3 of 4 wks 78 57 52*
   175 Gem 1000 mg/m2 d1, 8 + Exatecan 2 mg/m2 d1+8 q 3 wks 79 53 51*
  1. * KPS = 90–100%; PS = performance status;